Future cardiology · 2025
Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.
СтатьяПротокол клинического исследованияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Hong, Qian Si-Chong, Zhang Ying-Yuan, Tang Cheng-Bin, Yue Hong-Hua, Fan Guo-Liang, Zhao Xin, Jiang Yi-Yao, Huang Fu-Hua, Zeng Zhi-Hua, Wang Wei, Lu Xu-Ran, Luo Xiao-Kang, Bai Xiang-Feng, Zheng Xiang-Xiang, Xie Peng, Ma Chao, Zhao Sheng, Zhang Hong-Jia, On the behalf of China Additive Anti-inflammatory Actions for Aortopathy and Arteriopathy (5A) and PANDA Trial Investigators
Аннотация
This multicenter randomized controlled trial evaluates the efficacy of thymosin alpha 1 (Tα1) supplementation in preventing organ dysfunction following acute type A aortic dissection (ATAAD) repair. Over 330 patients will be equally assigned to receive either Tα1 plus standard care or placebo with standard management. The primary endpoint involves calculating the difference in mean postoperative Sequential Organ Failure Assessment (SOFA) scores between groups, measured daily from postoperative days 7. By targeting post-operative immune system imbalance, this study aims to establish a novel therapeutic approach for reducing systemic inflammatory response syndrome (SIRS)-mediated organ injury and improving long-term outcomes in this high-risk population. Results will be disseminated through peer-reviewed publications and international conferences.Trial registration: ClinicalTrials.gov Registry (NCT05339529).